Javitt, Daniel C.
Martinez, Antigona
Sehatpour, Pejman
Beloborodova, Anna
Habeck, Christian
Gazes, Yunglin
Bermudez, Dalton
Razlighi, Qolamreza R.
Devanand, D. P.
Stern, Yaakov
Funding for this research was provided by:
National Institutes of Health (R01MH49334, R01 AG041795, R01-AG026158)
Alzheimer's Drug Discovery Foundation
Article History
Received: 13 September 2022
Accepted: 12 February 2023
First Online: 28 February 2023
Declarations
:
: All procedures were approved by the institutional review boards of Columbia University and New York State Psychiatric Institute. All individuals signed written informed consent following a full explanation of the study procedures.
: Not applicable.
: DCJ, AM, and YS have filed intellectual property for use of visual ERP in the early detection of AD based on these results. DCJ also holds intellectual property for use of NMDAR agonists in schizophrenia, NMDAR antagonists in depression and PTSD, and MR-guided ECT and TMS treatment. DCJ is a scientific advisor to SK Life Sci, Biogen, and Boehringer Ingelheim; holds intellectual property for NMDAR-based treatment of schizophrenia and depression and in the use of parcel-guided TMS in depression; and holds equity in Glytech, Amino Acid Solutions, and NRx Pharma. DPD has received research grants from the National Institute on Aging and the Alzheimer’s Association and is a scientific adviser to Acadia, Biogen, Eisai, Genentech, Jazz Pharmaceuticals, and Novo Nordisk. YS is a scientific advisor to Eisai and Novic.